PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

- (51) International Patent Classification 6: (11) International Publication Number: WO 97/24116 A61K 31/19, 31/215, 31/34, 31/44 A3 (43) International Publication Date: 10 July 1997 (10.07.97) (21) International Application Number: PCT/US96/20511 (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, (22) International Filing Date: 16 December 1996 (16.12.96) HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, (30) Priority Data: UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), 08/580,553 29 December 1995 (29.12.95) Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), US European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, (71) Applicant: ALLERGAN [US/US]; 8301 Mars Drive, Waco, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
- (71) Applicant: ALLERGAN [US/US]: 8301 Mars Drive, Waco, TX 76712 (US).
 (72) Inventors: TENG, Min; 2 Dove Street, Aliso Vicio, CA 92656
- (US). DUONG, Tien, T.; Apartment 15C, 13 Bearpay, Irvine, CA 92714 (US). CHANDRARATNA, Roshantha, A.; 25841 Empresa, Mission Viejo, CA 92691 (US).
- (74) Agents: BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, T-2,2-E, P.O. Box 19534, Irvine, CA 92623-9534 (US).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

- (88) Date of publication of the international search report:
 13 November 1997 (13,11.97)
- (54) Title: METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR, RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY

(57) Abstract

Retinoid compounds which act specifically or selectively on RARo receptor subtypes in preference over RARo and RARr receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of funnors, such as acute monecylic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation actraogenicity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL.	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL.	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhetan	SI.	Slovenia
CI	Côte d'Ivoire	Li	Liochtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ.	Czech Republic	LU	Luxemboure	TG	Togo
DE	Germany	LV	Larvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	77	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzhekistan
		Charles of Street		O2	CARCADUM

INTERNATIONAL SEARCH REPORT Inter and Application No

			PCT/US 96/20511
ÎPC 6	SIFICATION OF SUBJECT MATTER A61K31/19 A61K31/215 A61	K31/34 A61K31,	/44
	to International Patent Classification (IPC) or to both nation	nal classification and IPC	
	OS SEARCHED		
IPC 0	documentation searched (classification system followed by c A61K		
Document	ation searched other than minimum documentation to the ext	ent that such documents are me	luded in the fields searched
Electronic	data base consulted during the international search (name of	data base and, where practical,	search terms used)
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate,	of the relevant passages	Relevant to claim ?
			Tenevan o cann
Х	WO 93 03713 A (SALK INST FOR STUDI) 4 March 1993	1-4, 6-12,	
	see page 9, line 4 - line 31;	14-22	
		-/	
i			
1			
X Furth	er documents are listed in the continuation of box C.	X Patent family m	unbers are listed in annex.
Special cate	rgories of cited documents:		
A" docume conside	nt defining the general state of the art which is not red to be of particular relevance	"I" later document public or priority date and cited to understand t	shed after the international filing date not in conflict with the application but he principle or theory underlying the
earlier d	ocument but published on or after the international	"Y" document of automat	
	nt which may throw doubts on priority claim(s) or seited to establish the publication date of another or other special reason (as specified)	involve an inventive	step when the document is taken slone
	nt referring to an oral disciosure, use, exhibition or	document is combine	ar relevance; the claimed invention to involve an inventive step when the id with one or more other such docu-
documen	tr published prior to the international filing date but in the priority date claimed	in the art.	and being divious to a person stilled
	ctual completion of the international search	'A' document member of	
	May 1997	30.09.97	international search report
ame and ma	uling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2230 HV Ripwijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Seegert,	K

INTERNATIONAL SEARCH REPORT Inter. ad Application No

		PCT/US 96/20511		
	C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	CHEMICAL ABSTRACTS, vol. 121, no. 9, 1994 Columbus, Ohio, US; abstract no. 108128d, XP002030814 see abstract & YU, BADXIN ET AL: "Synthesis of p-substituted benzoylaminobenzoic acid (methyl esters) and its differentiation induction activities of human promyelocytic leukemia cells HL-60" HUAXI YIKE DAXUE XUEBAO, vol. 25, no. 1, 1994, pages 30-34,	1-4, 6-12, 14-22		
Y	DATABASE WPI Section Ch, Week 9416 Derwent Publications Ltd., London, GB; Class B05, AN 94-128759 XP002030803 & JP 06 072 866 A (CHUGOKU IGAKUKAGAKUIN YAKUBUTSU KENKYUSH), 15 March 1994 see abstract	1-4, 6-12, 14-22		
Υ	EP 0 514 269 A (CIRD GALDERMA) 19 November 1992 see page 3, line 3 - page 3, line 9; claims 1-21 especially claim 16, ex. 15	1-4, 6-12, 14-22		
Y	EP 0 350 846 A (HOFFMANN LA ROCHE) 17 January 1990 see page 5, line 43 - page 6, line 35; claims 1-18	1-4, 6-12, 14-22		
Y	US 5 420 145 A (SHUDO KOICHI) 30 May 1995 see column 3, line 65 - column 4, line 29; claims 1-4	1-4, 6-12, 14-22		
Y	EP 0 170 105 A (SHUDO KOICHI ;SUMITOMO PHARMA (JP); YOSHITOMI PHARMACEUTICAL (JP)) 5 February 1986 see claims 1-11	1-4, 6-12, 14-22		
P, Y	WO 96 32101 A (TAIHO PHARMACEUTICAL CO LTD ;SHIBATA JIRO (JP); WIERZBA KONSTANTY) 17 October 1996 see abstract	1-4, 6-12, 14-22		
	-/			

INTERNATIONAL SEARCH REPORT | Inten | nal Application No

		PCT/US 96/20511
Category	DOCUMENTS CONSIDERED TO BE RELEVANT	
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KAGECHIKA H ET AL: "RETINOBENZOIC ACIDS STRUCTURE-ACTIVITY RELATIONSHIPS OF AROMATIC AMIDES WITH RETINOIDAL ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 11, November 1988, pages 2182-2192, XP6006608417 see tables I-VI see page 2187, left-hand column, last paragraph - page 2188, left-hand column	1-4, 6-12, 14-22
Ρ,Υ	MIN TENG ET AL: "Identification of a Retinoic Acid Receptor alpha Subtype Specific Agonist" J. MED. CHEM., vol. 39, no. 16, 2 August 1996, pages 3035-3038, XP000652115 see the whole document	1-4, 6-12, 14-22

INTERNATIONAL SEARCH REPORT

inte 'ional application No.

PCT/US 96/20511

Box i	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Info	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
з 🗌	Claims Nos: because they are dependent claims and are not dratted in accordance with the second and third sentences of Rule 6.4(e).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	omational Searching Authority found multiple inventions in this international application, as follows:
Se	e annex.
1.	As all required additional search less were timely paid by the applicant, this international Search Report covers all searchable claims.
2. 🗌	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-4,6-12, 14-22 (partially)
Remark	on Protest The additional search fees were accompanied by the applicant's protest.

FURTHER INFORMATION CONTINUED FROM PCT/ISAL 10

- 1. The use of a RAR alpha selective agonist for the prevention/treatment of acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas, head and neck carcinomas (respective portions of Claims 1- 4, 6-12, 14 22)
- 2. The use of a RAR alpha selective agonist for the prevention/treatment of proliferative vitreoretinopathy (PVR), age related macular degeneration (AMD), diseases of the eye, retinal detachment, dry eye, other corneopathies (respective portions of Claims 1 - 22)
- 3. The use of a RAR alpha selective agonist for the prevention/treatment of actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichtyoses, eczema, atopic dermatitis, Darriers disease, lichen planus, skin pigmentation, age and photo damage to the skin, premalignant and malignant hyperproliferative diseases, Kaposi's sarcoma (respective portions of Claims 1, 2, 4 13, 15- 22)
- The use of a RAR alpha selective agonist for the prevention/treatment of cardiovascular diseases (respective portions of Claims 1, 2, 4 - 13, 15-22)
- 5. The use of a RAR alpha selective agonist for the prevention/treatment of dyslipidemias (respective portions of Claims 1, 2, 4 13, 15- 22)
- The use of a RAR alpha selective agonist for the prevention of post-angioplasty restenosis (respective portions of Claims 1, 2, 4 - 13, 15- 22)

FURTHER INFORMATION CONTINUED FROM PCT/ISAP 10

- 7. The use of a RAR alpha selective agonist for the prevention/treatment of diseases associated with human papilloma virus (HPV) (respective portions of Claims 1, 2, 4 13, 15- 22)
- 8. The use of a RAR alpha selective agonist for the for the prevention/treatment of inflammatory diseases (respective portions of Claims 1, 2, 4 13, 15-22)
- 9. The use of a RAR alpha selective agonist for the prevention/treatment of neurodegenerative diseases (respective portions of Claims 1, 2, 4 13, 15- 22)
- 10. The use of a RAR alpha selective agonist for the prevention/treatment of improper pituitary function (respective portions of Claims 1, 2, 4 13, 15-22)
- 11. The use of a RAR alpha selective agonist for the prevention/treatment of insufficient hair growth (respective portions of Claims 1, 2, 4 13, 15-22)
- 12. The use of a RAR alpha selective agonist for the prevention/treatment of diseases associated with the immune system (respective portions of Claims 1, 2, 4 13, 15- 22)
- 13. The use of a RAR alpha selective agonist for wound healing (respective portions of Claims 1, 2, 4 13, 15-22)

The search has been limited to the subject-matter of item 1.

INTERNATIONAL SEARCH REPORT Listen and Application No

information on patent family members

PCT/US 96/20511

			, ,
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9303713 A	04-03-93	AU 2516092 CA 2114936 EP 0600028 JP 7505607 US 5668175	A 04-03-93 A 08-06-94 T 22-06-95
EP 0514269 A	19-11-92	FR 2676440 / AT 129698 AU 650972 AU 1627392 / CA 2668696 DE 69205725 DE 69205725 TE 2080458 JP 5221951 A	T 15-11-95 3 07-07-94 4 19-11-92 4 16-11-92 0 07-12-95 T 30-05-96
EP 0350846 A	17-01-90	AT 128974 T AU 626881 B AU 3709789 A CA 1319364 A DE 589993463 D ES 2078995 T FI 96204 B IL 99912 A JP 2053684 C JP 2076862 A JP 2076862 A JP 191158 B US 5420273 A US 5037825 A US 5307825 A US 5307825 A US 530822 A MX 16751 A	3 13-08-92 18-01-90 22-06-93 16-11-95 01-01-96 15-02-96
US 5420145 A	30-05-95	EP 0617020 A	28-09-94
EP 0170105 A	05-02-86	JP 1764534 C JP 4058458 B JP 61022047 A	28-05-93 17-09-92 30-01-86

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern al Application No PCT/US 96/20511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0170105 A		JP 1764542 C JP 4058459 B JP 61076440 A US 4703110 A	28-05-93 17-09-92 18-04-86 27-10-87
WO 9632101 A	17-10-96	AU 5287596 A CA 2191850 A EP 0768084 A	30-10-96 17-10-96 16-04-97